Know Cancer

forgot password

Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal RT for Prostate Cancer

Not Enrolling
Prostate Cancer

Thank you

Trial Information

Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal RT for Prostate Cancer

OBJECTIVES: Major innovations in radiotherapy (RT) delivery (3D conformal RT, intensity
modulated RT) now permit RT dose escalation to be tested as a means of improving control of
localized prostate cancer. With delivery innovations, severe toxicity occurs rarely, but
significant bladder and rectal toxicity is common. The investigators have studied a cohort
of 98 patients who received dose-escalated 3D-CRT and have obtained evidence of dosimetric
factors underlying rectal toxicity. They posit that the late radiation toxicity disease
state has significant genetic determinants. These determinants are neither understood nor
accounted for in selection of treatment, and the investigators propose to study the above
well-characterized cohort, who are clinically well from a disease control perspective, given
that comprehensive dosimetric and outcome information is available on all.

HYPOTHESIS: Comprehensive analysis of the genomic, proteomic, and dosimetric characteristics
of patients with prostate cancer will provide a novel understanding of the genetic
predisposition of cellular and tissue responses to irradiation which result in the clinical
occurrence of significant chronic rectal and bladder injury after 3D-CRT.

APPROACH: For a thorough understanding of the molecular processes underlying tissue
responses to radiation damage, the investigators propose a genomic analysis. Their working
hypothesis is that rectal and bladder toxicity will be correlated to patient genetics as
measured by single nucleotide polymorphisms (SNPs) in a select group of genes. The criteria
for selecting SNPs will be based on evidence for the various genes implicated or
demonstrated in DNA repair pathways and radiation-induced tissue damage. In addition, since
radiation injury can be considered a phenotypic tissue response to RT in genetically
predisposed individuals, the investigators will examine the protein profile "signature" in
sera from patients who have suffered significant toxicity. Analysis of these data will be
unique in that the investigators will use both statistically based bioinformatics
approaches, and biophysical modeling. This proposal represents the most comprehensive
exploration to date of the concept of a molecular "signature" of normal tissue radiation
injury of which the applicants are aware.


- To create a database of SNPs among long-term prostate cancer survivors who have been
treated with 3D-CRT, and for whom detailed toxicity, quality of life and dosimetric
information are available;

- To assess the feasibility of using bioinformatics approaches with this database to
examine the possibility that specific SNPs, in the context of known dosimetric factors,
can predict occurrence of late rectal or bladder toxicity;

- To perform a proteomic analysis of serum samples from a cohort of 25 patients
experiencing higher levels of ongoing late toxicity and 50 patients with no ongoing
late toxicity.


- To utilize biophysical approaches to modelling clinical complication data, using the
concept of generalized mean biological effective dose (GMBED) and the critical volume

SUMMARY: This proposal will be the first comprehensive retrospective analysis of genomic,
proteomic and dosimetric determinants of late radiation injury in prostate cancer. The
investigators have assembled a broad array of expertise from the CCI PolyomX program (the
only high throughput SNP facility in western Canada), the NCI/FDA Clinical Proteomics
Program at Bethesda, MD, and the unique biophysical modeling capability of CBIAR researchers
to reach these goals.

Inclusion Criteria:

- Treatment with 3D CRT for which follow-up toxicity evaluation was done

Exclusion Criteria:

- Follow-up less than 18 months

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Retrospective

Principal Investigator

Matthew Parliament, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cross Cancer Institute


Canada: Health Canada

Study ID:

GU-6-0035/ethics 17075



Start Date:

April 2003

Completion Date:

January 2012

Related Keywords:

  • Prostate Cancer
  • prostate cancer
  • radiotherapy
  • radiation toxicity
  • single nucleotide polymorphism
  • Prostatic Neoplasms